a prospective cohort study evaluating safety and efficacy of leuprolide acetate different depot formulations in young patients with hormone receptor-positive breast cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068147

Enrollment

Unknown

Registered

2023-02-08

Start date

2023-02-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

1-month leuprolide group:N/A

3-month leuprolide group:N/A

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 18 years = age = 40 years female; Hormone receptor-positive breast cancer confirmed by surgery or biopsy (immunohistochemical test ER or PR (progestogen receptor) =10%), HER-2(-)TNM I-III; Received leuprolide (manufacturer is Takeda Pharmaceutical Co., Ltd.) + TAM/AI;Agree to participate in this study

Exclusion criteria

Exclusion criteria: GnRHa is used for chemotherapy ovarian function protection; Ovariectomy, ovarian radiotherapy, or associated ovarian disorders during treatment; Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
The standard rate of estradiol =30 pg/ml;	—

Secondary

Measure	Time frame
Levels of follicle-stimulating hormone and luteinizing hormone;Disease-free survival;Menstruation;Occurrence of adverse events;	—

Countries

CHINA

Contacts

Public ContactLI CHUNBAO

Jinjiang Municipal Hospital

766116520@qq.com18259591581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026